Invention Grant
US07928105B2 Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones
有权
取代的6a，7,8,9-四氢吡啶并[3,2-e]吡咯并[1,2-a]吡嗪-6（5H） - 酮
![Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones](/docs/US/2011-04-19/US07928105B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones
- Patent Title (中): 取代的6a，7,8,9-四氢吡啶并[3,2-e]吡咯并[1,2-a]吡嗪-6（5H） - 酮
-
Application No.: US12691668Application Date: 2010-01-21
-
Publication No.: US07928105B2Publication Date: 2011-04-19
- Inventor: Anthony R. Gangloff , Andrew John Jennings , Benjamin Jones , Andre A. Kiryanov
- Applicant: Anthony R. Gangloff , Andrew John Jennings , Benjamin Jones , Andre A. Kiryanov
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agent Matthew J. Russo; Mitchell R. Brustein
- Main IPC: A61K31/495
- IPC: A61K31/495
![Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones](/abs-image/US/2011/04/19/US07928105B2/abs.jpg.150x150.jpg)
Abstract:
Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R31, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
Public/Granted literature
- US20100190763A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Public/Granted day:2010-07-29
Information query
